Compare ALK & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALK | BLCO |
|---|---|---|
| Founded | 1932 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.0B |
| IPO Year | 2003 | 2022 |
| Metric | ALK | BLCO |
|---|---|---|
| Price | $34.10 | $15.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $63.92 | $18.55 |
| AVG Volume (30 Days) | ★ 4.7M | 387.5K |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $10,426,000,000.00 | $5,101,000,000.00 |
| Revenue This Year | $9.26 | $8.63 |
| Revenue Next Year | $5.66 | $5.58 |
| P/E Ratio | $43.56 | ★ N/A |
| Revenue Growth | ★ 8.09 | 6.47 |
| 52 Week Low | $35.89 | $10.45 |
| 52 Week High | $65.35 | $18.92 |
| Indicator | ALK | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 26.73 | 32.59 |
| Support Level | N/A | $14.39 |
| Resistance Level | $53.49 | $17.66 |
| Average True Range (ATR) | 1.81 | 0.48 |
| MACD | -0.07 | -0.13 |
| Stochastic Oscillator | 11.60 | 4.59 |
Alaska Air Group Inc operates two airlines, Alaska and Horizon, in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements. The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary, and Mileage Plan passenger revenue.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.